MedWatch

Novo Nordisk's Ozempic is the preferred GLP-1 analogue in Denmark

The Danish Health Authority has appointed Novo Nordisk's new drug Ozempic as first choice of GLP-1 analogues for treating type 2 diabetes. However, it does not apply to patients with cardiovascular problems or the eye disease diabetic retinopathy.

Foto: /ritzau/AP/Novo Nordisk

Novo Nordisk's next potential growth generator, Ozempic, is now the preferred drug in its class on the Danish market.

The Danish Health Authority's initiative for Rational Pharmacotherapy (IRF) recently issued a drug review classifying Ozempic (semaglutide) as be the preferred choice for patients with type 2 diabetes to be treated with a GLP-1 analogue.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier